A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study)

Autor: Nguyen Van Kinh, Nguyen Dat Anh, Chian Min Loo, Eddy Harijanto, Wai Ming Chan, Christopher W. Lee, Mahiran Mustafa, Jemelyn Garcia
Rok vydání: 2014
Předmět:
Acinetobacter baumannii
Male
Pediatrics
law.invention
law
Medicine
Pharmacology (medical)
Prospective Studies
Escherichia coli Infections
Aged
80 and over
education.field_of_study
biology
Mortality rate
Pneumonia
Ventilator-Associated
General Medicine
Middle Aged
Intensive care unit
Anti-Bacterial Agents
Intensive Care Units
Klebsiella pneumoniae
Treatment Outcome
Infectious Diseases
Pseudomonas aeruginosa
Urinary Tract Infections
Vomiting
Female
medicine.symptom
Acinetobacter Infections
medicine.drug
Adult
Microbiology (medical)
medicine.medical_specialty
Asia
Adolescent
Population
Young Adult
Internal medicine
Escherichia coli
Humans
Pseudomonas Infections
Adverse effect
education
Aged
business.industry
Doripenem
biology.organism_classification
medicine.disease
Klebsiella Infections
Pneumonia
Carbapenems
Intraabdominal Infections
business
Zdroj: International Journal of Antimicrobial Agents. 43:353-360
ISSN: 0924-8579
DOI: 10.1016/j.ijantimicag.2014.01.017
Popis: Doripenem is approved in the Asia-Pacific (APAC) region for treating nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP), complicated intra-abdominal infections (cIAIs) and complicated urinary tract infections (cUTIs). Clinical usage of doripenem (500mg intravenously, infused over 1h or 4h every 8h for 5-14 days) in APAC was evaluated in a prospective, open-label, non-comparative, multicentre study of inpatients (≥18 years) with NP, VAP, cIAI or cUTI. A total of 216 [intention-to-treat (ITT)] patients received doripenem: 53 NP (24.5%); 77 VAP (35.6%); 67 cIAI (31.0%); and 19 cUTI (8.8%). Doripenem MIC90 values for Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli and Klebsiella pneumoniae were 32, 32, 0.094 and 0.64μg/mL, respectively. Doripenem was used most commonly as monotherapy (86.6%) and as second-line therapy (62.0%). The clinical cure rate in clinically evaluable patients was 86.7% at the end of therapy (EOT) and 87.1% at test of cure (TOC) (7-14 days after EOT). In the ITT population, overall clinical cure rates were 66.2% at EOT and 56.5% at TOC. The median duration of hospital stay, intensive care unit (ICU) stay and mechanical ventilation was 20, 12 and 10 days, respectively. Of 146 discharged patients, 7 were re-admitted within 28 days of EOT; 1 VAP patient was re-admitted to the ICU. The all-cause mortality rate was 22.7% (49/216). The most common treatment-related adverse events were diarrhoea (1.4%) and vomiting (1.4%). Doripenem is a viable option for treating APAC patients with NP, VAP, cIAI or cUTI. [ClinicalTrials.gov: NCT 00986102].
Databáze: OpenAIRE
Externí odkaz: